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Recent advances in the structural molecular
biology of Ets transcription factors: interactions,
interfaces and inhibition
Christopher D.O. Cooper*1, Joseph A. Newman* and Opher Gileadi*
*Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Old Road Campus, Headington, Oxford OX3 7DQ, U.K.
Abstract
The Ets family of eukaryotic transcription factors is based around the conserved Ets DNA-binding domain.
Although their DNA-binding selectivity is biochemically and structurally well characterized, structures of
homodimeric and ternary complexes point to Ets domains functioning as versatile protein-interaction
modules. In the present paper, we review the progress made over the last decade to elucidate the structural
mechanisms involved in modulation of DNA binding and protein partner selection during dimerization. We
see that Ets domains, although conserved around a core architecture, have evolved to utilize a variety of
interaction surfaces and binding mechanisms, reflecting Ets domains as dynamic interfaces for both DNA
and protein interaction. Furthermore, we discuss recent advances in drug development for inhibition of Ets
factors, and the roles structural biology can play in their future.
Introduction
The Ets TF (transcription factor) family is found throughout
the metazoa, comprising 28 members in humans [1,2],
all containing the evolutionarily conserved DNA-binding
Ets domain which binds the invariant DNA sequence 5′-
GGA(A/T)-3′ [2]. Ets TFs play important roles in normal
cellular development and differentiation [3], but when
deregulated are significant mediators of tumorigenesis in
various cancers [4,5]. Ets proteins are subclassified by the
presence of further domains associated with PPIs (protein–
protein interactions) or transcriptional regulation [2,3],
including the TCF (containing the B-box [6]) and PEA3
(containing the unstructured PEA3 transactivation domain
[7]) subfamilies. PNT (pointed) domains are also frequently
found N-terminal to the Ets domain, involved in PPI and
homodimerization [8,9] (Figure 1A).
Although different Ets TFs may bind similar DNA
sequences and are expressed in multiple cell-dependent com-
binations, much of their binding specificity and regulation is
mediated directly by the structurally conserved Ets domain.
A number of Ets protein structures have been determined,
either individually or as binary or ternary complexes
with interaction partners or DNA (comprehensively listed
elsewhere [2] and in Table 1). These structures have shed
light on some mechanisms used to regulate Ets function,
particularly interaction interfaces utilized in binding co-
operativity and sequence selectivity of Ets ternary complexes
on tandem DNA motifs [10–12]. A number of homodimeric
Key words: cancer, dimerization, Ets transcription factor, protein–DNA ternary complex, protein–
protein interaction.
Abbreviations: EBS, Ets-binding site; PNT, pointed; PPI, protein–protein interaction; RHA, RNA
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Ets domain structures have also helped to elucidate
mechanisms of autoinhibition of DNA binding compared
with co-operative binding [13–15].
Such structural studies have demonstrated the evolution
of multiple independent PPI interfaces on Ets domains,
thereby illustrating their versatile nature, not only responsible
for binding DNA, but also critical for the regulation
of DNA binding and transcriptional activity. As Ets
proteins are central to cancer development and progression,
Ets PPI interfaces are clear targets for abrogation by
chemotherapeutic drugs [5,16]. In the present paper, we
review existing and recent progress on structural studies of
Ets interaction and interfaces, with the prospect of exploiting
these surfaces as drug targets and to further our understanding
of Ets regulation.
Ets proteins in biology and cancer
development
Ets TFs are expressed ubiquitously or in tissue-specific
patterns [17] and are particularly involved in differentiation
processes such angiogenesis [18] and haemopoiesis [19].
PEA3 proteins play particular roles in branching morpho-
genesis and limb development [20]. Genetic knockouts
suggest functional redundancy of some Ets factors [21], and
genome-wide analyses show both specific and redundant
Ets occupancy in promoter-proximal regions [22], reflecting
plasticity in Ets transcriptional regulation.
As Ets TFs regulate activation or repression of key
developmental or homoeostatic target genes, it is not
surprising that Ets deregulation is a driving force in neoplastic
transformation, metastasis and progression [4]. Ets overex-
pressionmay followchromosome rearrangements, fromcopy
gains of ETV1 in melanoma [23], to fusion of ERG or ETV1
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Figure 1 Structure of Ets domain transcription factors
(A) Domain architecture of representative members of the Ets family, with domains and lengths not to scale. Only structured
domains rather than transactivation/inhibitory domains are shown (upper panel). Expansion represents the core Ets domain
secondary structure (lower panel). Core Ets domain secondary-structural elements are green rectangles (α-helices/H) and
yellow arrows (β-sheet/β), with appended α-helices shown where appropriate. (B) Cartoon representation of a typical
core Ets domain fold (ELK4, PDB code 1K6O [11]). Secondary-structural elements are coloured and labelled according to
(A). (C) Structural diversity amidst a conserved core. Cartoon representation of a core Ets fold (ELK4), with superimposed
appended helices represented as cylinders where appropriate. Secondary-structural elements are coloured and labelled
according to (A). Two alternative conformations of ETS1 helix HI-1 are shown (light blue, uninhibited, PDB code 3MFK [15])
and autoinhibited (dark blue, PDB code 1R36 [36]), with the inhibited ETV6 additional helices represented in orange (PDB
code 2DAO [38]).
C©The Authors Journal compilation C©2014 Biochemical Society
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Table 1 Ets domain complexes and structural information
The list is not exhaustive, but provides an overview of the variety of Ets protein interactions characterized biochemically and structurally in the
literature. N/R, no record.
Ets domain Interaction type Protein partner PDB code Interface details Reference
ETS1 Homodimer ETS1 2NNY Head-to-head Ets domains on palindromic EBS. HI-2
and HI-2/H1 loop contact H2-H3 loop reciprocally
(‘Area I’)
[42]
ETS1 Homodimer ETS1 3MFK Similar to Area I in 2NNY on palindromic EBS.
Additional contacts between dimer units, with HI-1
contacting H4, HI-2 and HI-1/HI-2 loop reciprocally
(‘Area II’)
[14]
ETS1 Homodimer ETS1 3RI4 Interface similar to Area II from 3MFK, but on two
separate EBS units
[15]
ETS1 Heterodimer PAX5 1K78 PAX5 β-hairpin Gln22 hydrogen-bonds to reposition
ETS1 Tyr395 in Ets helix H3
[12]
ETS1 Heterodimer FOXO1 4LG0* Ets domain interaction N/R
ETS1 Heterodimer AML1 3W46† Autoinhibitory regions from each partner interact to
reciprocally relieve inhibition of DNA binding
[64]
ELK4 (SAP1) Heterodimer SRF 1K6O SRF MADS domains N-terminal Leu155 fits into small
pocket comprising Ets H1, H4 and H5 and the H3 on
Ets H3, reorienting Tyr65 and Arg64 to enhance DNA
binding
[11]
SPI1 (PU.1) Heterodimer IRF4 N/R Ets H2-H3 loop contacts IRF4 across the DNA minor
groove
[48]
SPI1 (PU.1) Heterodimer AP-1 (JUN) N/R Jun basic domain binds Ets β3-β4 region [65]
SPI1 (PU.1) Heterodimer NF-IL6 N/R Ets domain interacts through β2-α2-α3 and β3-β4
elements
[53]
GABPα Heterodimer GABPβ 1AWC GABPβ ankyrin repeat loops bind cleft comprising Ets
H1, H4 and H5 and the H3-β3 loop
[47]
ERG Heterodimer DNA-PKcs N/R Involves Tyr373 at the edge of the H3 helix [29]
ERG Heterodimer AR N/R Involves Ets domain H3-β3-β4 region [54]
ERG Heterodimer AP-1 (JUN) N/R Jun basic domain binds Ets H3 region [52]
ETV1 Heterodimer AR N/R Involves Ets and upstream regions [66]
ETV1 Homodimer ETV1 4AVP, 4BNC Reciprocal contacts between H1, H4 and the β1-β2
loop; significant hydrophobic area and intersubunit
disulfide bond
(C.D.O. Cooper, J.A.
Newman, C.K.
Allerston and O.
Gileadi, unpublished
work)
FEV Homodimer FEV 2YPR, 3ZP5 Reciprocal contacts between H1, H4 and the β1-β2
loop; significant hydrophobic area and intersubunit
disulfide bond
(C.D.O. Cooper, J.A.
Newman, C.K.
Allerston and O.
Gileadi, unpublished
work)
ELK1 Homodimer ELK1 1DUX Reciprocal contacts between Ets H1/H1-β1 loop [43]
*PDB record on hold
†One of many PDB records on hold
to the TMPRSS2 promoter, resulting in androgen-inducible
expression in prostate cancer [24], associated with aggressive
disease [25]. Chromosomal translocations are prevalent in
Ewing’s sarcomas, where the EWS transactivation domain
is fused to Ets domains of ETV1, ETV4, ERG, FLI1 or
FEV, dominantly activating transcription of Ets targets [26].
Cancer development is hence likely to be mediated by Ets
target genes driving various stages of the neoplastic process,
e.g. immortalization following hTERT (human telomerase
reverse transcriptase) up-regulation [27] or E2F cell cycle
disruption [28], increased DNA damage [29], or metastasis
following matrix metalloproteinase up-regulation [30].
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Ets transcription factor structure
Ets TFs are modular proteins with the Ets domain generally
present at either terminus [2] (Figure 1A). Ets domains
comprise a small (∼85-residue) four-stranded antiparallel β-
sheet packed against three semi-orthogonal α-helices in a
variant helix–turn–helix (winged helix) conformation [31]
(Figures 1A and 1B). Ets domains can bind ∼15 bp dsDNA
with a 10 bp specificity at EBSs (Ets-binding sites), where the
H3 helix acts in DNA recognition by inserting in the major
groove, allowing conserved arginine and tyrosine residues
to hydrogen-bond bases in the consensus 5′-GGA(A/T)-3′
motif [2]. Ets proteins are grouped into four classes on the
basis of DNA-binding specificity, reflecting residues in helix
H3 and the H3–β3 loop [32]. The mechanism for DNA
sequence recognition outside the GGA(A/T) core is less
clear, with indirect readout suggested as a contributing factor
[33]. Given this overlap in Ets recognition sequences, further
specificity is extended by combinatorial and co-operative
binding with other TFs [10] at tandem (e.g. ETS1/RUNX
[34]) or palindromic sites (ETS1) [35] respectively.
DNA binding may be regulated by sequences bordering
the Ets; for instance, ETS1 DNA binding is inhibited by
two helices flanking each side of the Ets. These form a
helical bundle which packs against helix H1 distal to the
DNA-binding face [13] (Figure 1C), with the metastable
HI-1 of the inhibitory bundle unfolding on DNA binding
[36]. Studies on ERG suggest allosteric inhibition may
result from stabilization of the conformation of a conserved
tyrosine residue on helix H3, which is less optimal for DNA
binding, or by reducing polypeptide backbone dynamics in
the inhibited state [37]. In a further mechanism, two helices
appended to the ETV6 Ets C-terminus can inhibit DNA
binding by steric blocking [38] (Figure 1C).
Ets domains as protein–protein interaction
modules
Many eukaryotic TFs act as non-covalent dimers, with
interaction critical for function, mediated by DNA-binding
domains or through additional subunits [39]. Ets TFs can
dimerize using the Ets domain and/or additional domains
such as PNT [9], with Ets-mediated interactions either
homodimeric or heterodimeric with other TFs or protein
partners (Table 1). Homodimerization allows co-operative
binding to repeated DNA elements [35], with heterodimeric
interactions with non-Ets proteins potentiating combinator-
ial control of DNA binding [40], crucial for tissue-specific
transcriptional regulation.
Homodimeric Ets complexes
Perhaps the most structurally studied Ets protein is ETS1
[41], existing as an autoinhibited monomer in solution,
although domain-swapped dimers have been crystallized in
the absence of DNA [13]. Monomeric ETS1 can bind to
singleEBSmotifs, or co-operatively in dimeric configurations
at palindromic sites such as the stromelysin-1 promoter
[35], thereby counteracting its autoinhibition. Two protein
interface areas are observed in different ETS1–DNA ternary
structures, with Area I involving a head-to-head dimeric
arrangement orthogonal to the DNA-binding face (PDB
codes 2NNY [42] and 3MFK [14]) (Figure 2A), and Area
II involving domain-swapped interactions between two sets
of juxtaposed ETS1 dimer units (3MFK [14] and 3RI4
[15]). Area I comprises reciprocal hydrogen bonds and van
der Waals interactions from helix HI-2 and the HI-2/H1
loop to the H2-H3 loop, between opposing subunits. This
buries ∼370 A˚2 (1 A˚ = 0.1 nm) of monomer surface and
the 4 bp spacing between palindromic EBSs is critical for
this interaction as the HI-2/H1 loop interacts with the
minor groove in this region. The Area II domain-swapped
interface between two sets of dimers buries 650 A˚2, with
the N-terminus of HI-1 contacting H4, HI-2 and the HI-
1/HI-2 loop on the opposing dimer. Recently, a similar
Area II interface was reported for another dimeric ETS1
configuration,with anETS1dimer complexed to two separate
dsDNA duplexes in an antiparallel EBS configuration (PDB
code 3RI4 [15]) (Figure 2B).Here, additional hydrogenbonds
are found between oneETS1 subunit and neighbouringDNA
bound by the other ETS1 subunit. Although the ETS1 (PDB
code 3RI4) Area II interface and local structure is similar to
ETS1 (PDB code 3MFK), the Ets domains are in differing
orientations allowing the DNA to run parallel, reflecting
flexibility of the N-terminal region. This arrangement may
allow widely separated EBSs to be brought together by
looping in vivo, potentially at nucleosomes [15].
Homodimeric arrangements are found in further Ets
domains; for instance, the TCF member ELK1 crystal
structure (1DUX [43]) (Figure 2C) has a reciprocal interface
between monomers at the C-terminal end of the helix H1
and H1-β1 loop, involving three pairwise hydrogen bonds
[44]. Although this buries a similar area to ETS1 (480 A˚2),
the dimerization interface is different as ELK1 does not
have the additional helices of ETS1. This arrangement orients
theELK1monomerswith theirDNA-binding faces onnearly
opposite sides of the dimer interface, hence they could not
bind closely separated EBS motifs, unlike the head-to-head
ETS1 structure. ELK1 Ets dimerization is observed in vitro
and in vivo with the H1-β1 loop required for dimerization
and cytoplasmic stability [45]. Recent structures of ETV1
(PDB code 4AVP) (Figure 2D) and FEV (PDB code 2YPR
(Figure 2E) Ets domains reveal a further significant dimeric
interface (C.D.O. Cooper, J.A. Newman, C.K. Allerston
and O. Gileadi, unpublished work), with reciprocal contacts
involving H1, H4 and the β1-β2 loop burying >700 A˚2.
Although contacts are predominantly non-polar, a hydrogen
bond and significantly, an intermolecular disulfide linkage
are also present. This interface juxtaposes ETV1 subunits in a
different orientation and surface position relative to FEV and
the ELK1 homodimers, although similarly positioning the
H3 helix to preclude binding close or tandem EBS sequences.
Complexes of Ets and other proteins
Ets factors are promiscuous partners in PPI networks [9,40],
with a number of structurally characterized heterodimeric
C©The Authors Journal compilation C©2014 Biochemical Society
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Figure 2 Structural comparison of Ets homo- and hetero-dimeric complexes
Ets ternary PDB structures were superimposed against one Ets subunit (blue), whereas the relative position of interacting Ets
or other protein partners are in orange. Additional subunits not interacting with Ets domains are in red/orange, with dsDNA
in grey. (A) ETS1 (PDB code 3MFK) showing Area I interface (note that HI-1 helices do not contact). (B) ETS1 (PDB code 3RI4)
showing Area II interface. (C) ELK1 (PDB code 1DUX). (D) ETV1 (PDB codes 4AVP and 4BNC). (E) FEV (PDB codes 2YPR and
3ZP5). (F) GABPα–GABPβ (PDB code 1AWC). (G) ETS1–PAX5 (PDB code 1K78). (H) ELK4–SRF (PDB code 1K6O).
C©The Authors Journal compilation C©2014 Biochemical Society
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ternary interactions on DNA involving Ets domains,
elucidating the role of interaction interfaces [10]. The GABP
TF heterodimeric structure (PDB code 1AWC) (Figure 2F)
comprises the Ets domain of the GABPα subunit complexed
with the ankyrin repeat-containing GABPβ subunit [47].
The interface buries a significant 1600 A˚2 in total, mainly
involving hydrophobic contacts, but also some water-
mediated hydrogen bonds. This involves the tips of the
GABPβ ankyrin repeats fitting into a depression formed
by H1, H4 and H5 of GABPα, along with the H3-β3
loop. Although this positions GABPβ in a similar relative
juxtaposition to one subunit in the ETV1 dimer, this interface
is specific for GABPα as ETS1 cannot bind GABPβ [47].
Whereas theGABPα/β heterodimer bindsDNAwith greater
affinity than GABPα alone, GABPβ does not contact
DNA directly. Instead, an indirect hydrogen bond from
GABPβ Lys69 to GABPαGln321 to the DNA phosphate may
strengthen interaction, but reorientation of theH5 helix away
from the DNA interface could also be involved, analogous to
ETS1 autoinhibition [47].
A very different Ets domain ternary interface is illustrated
by the ETS1–PAX5 complex with the mb-1 promoter (PDB
code 1K78) [12].Here, one of the PAX5paired domains binds
its cognate DNA on the opposite side of the DNA duplex
from ETS1, with only 180 A˚2 of monomer surface buried
in the ETS1–PAX5 interface. Yet, this interaction is critical
for binding the low-affinity mb-1 promoter, as the PAX5
β-hairpin Gln22 repositions the conserved Tyr395 side chain
in ETS1 helix H3 to form more optimal DNA contacts. In
addition, PAX5 forms further van der Waals and salt bridge
contacts to ETS1. Hence the DNA-binding H3 helix is key
to both protein–DNA and PPIs. This is analogous to the
heterodimeric interface from the SRF–ELK4 (SAP1) ternary
structure with DNA (PDB code 1K6O [11]). Although
the primary interaction of the SRFMADS domain is with the
ELK4 C-terminal B box, a similar stabilization of optimal
DNA contacts as seen with ETS1–PAX5 occurs following
SRF binding to its cognate DNA sequence and ELK4. Here,
a small hydrophobic pocket comprising residues from the
ELK4 helix H3 accommodates the N-terminal SRF Leu155,
reorienting a conserved tyrosine and arginine residue tomake
additional DNA contacts [11]. SPI1 (PU.1) also forms an
interface across the minor groove with IRF4, where IRF4
binding increases co-operativity up to 40-fold, presumably
involving the shift of SPI1 from participating in a salt bridge
with the DNA backbone to one with IRF4 [48]. Hence
binding of Ets domains to their heterodimeric partners allows
a dynamic change in co-operative binding properties, with
SPI1 gaining binding energy from interacting with IRF4, and
both PAX5 and SRF assistingETS1, not by providing binding
energy, but from optimizing binding to low-affinity DNA
sequences.
Although further Ets heterodimeric interactions have been
reported, structural information is currently scarce (Table 1).
The heterodimeric AP-1 TF is involved in cell proliferation
[49] and binds to a number of Ets domains through the Jun
basic domain [50]. SPI1 interacts via the β3/β4 elements
close to helix H3 where GATA TFs compete to bind and
hence repress SPI1 transactivation [51]. The β3/β4 region
is not required for interaction with ERG, however [52],
reflecting functional diversity within this structural scaffold.
Instead, the ERG helix H3 Tyr371 and Arg367 are critical for
Jun interaction [52]. Of particular note, the proximal Tyr373
at the edge of ERG helix H3 can mediate an interaction
with DNA-PKcs (DNA-dependent protein kinase catalytic
subunit) directly in aDNA-independentmanner, required for
ERG-driven transcription and neoplastic effects [29]. SPI1
also interacts with NF-IL6 (nuclear factor for interleukin
6 expression) [C/EBPβ (CCAAT/enhancer-binding protein
β)] through the β2-α2-α3 and β3-β4 regions [53]. The
importance of these additional Ets interaction partners merits
structural study, as some interfaces appear to be novel
and even if such surfaces appear similar to those already
characterized, subtle residue movements are key to co-
operative binding on DNA [11,12]. Furthermore, many
structurally uncharacterized Ets domain interactions involve
other TFs central to cellular development or neoplasia, such
as the androgen receptor [54], HOX homeodomains [55] and
forkheadTFs, although anETS1–FOXO1 (forkhead boxO1)
structure (PDB code 4LG0) is currently on hold in the PDB.
Ets domains as conserved yet versatile
interaction interfaces
Although Ets domains act as flexible PPI modules with
multiple partners as described [9,40] (Table 1), they
exhibit strong sequence and structural identity. Interaction
specificity is therefore likely to be determined by appended
helices and small residue substitutions (e.g. SPI1 lacks
two conserved tyrosine residues in helix H3). Relative
juxtapositioning of Ets interaction partners demonstrates
that structurally determined interaction interfaces are limited
to two areas (Figure 2). Interactions involving the DNA-
recognition helix H3 across the DNA duplex unsurprisingly
associate with structural changes relating to DNA-binding
modulation. Other interfaces are on the face containing
helix H1 and appended helices, but bound at a variety
of sites within this region. This may reflect the diversity of
appended helices providing multiple binding solutions
(Figure 1C). Of note, however, is the lack of involvement of
the opposite face containing the β3-β4 loop and surface of the
β-sheet (Figure 2). As described, a number of biochemically
characterized interactions involve these regions (e.g. SPI1–
AP-1 [51]), hence future structural determination of such
interactions is important.
Ets transcription factors as targets for
inhibition in cancer
TFs play a direct role in transformation andmetastasis during
cancer development, and their modulation or inhibition
has long been a major aim of translational cancer research
[56]. As described above, overexpressed Ets TFs are major
players in cancer development and can drive aggressive
C©The Authors Journal compilation C©2014 Biochemical Society
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disease, hence they have been identified as significant targets
for drug development [5,56]. A number of strategies are
available for TF drug targeting [16], and early attempts to
target Ets TF–DNA interactions used oligonucleotides
to mimic the EBSs and saturate ETS1 [57], or target EBS
motifs directly to bind the minor groove in a sequence-
dependent manner, occluding Ets domain binding [58]. The
similarity of EBS motifs, however, could limit this method,
but abrogation of Ets PPI interfaces presents an attractive
alternative avenue for small-molecule targeting. These have
promise as potential inhibitors, but, although PPI interfaces
often display a lack of defined binding pockets, small
molecules often have pharmacokinetic properties superior to
those of peptide inhibitors [16] and greater chemical space
can be explored [59]. For instance, the imidazoline derivative
Nutlin-3a inhibits the p53–MDM2 (murine double minute
2) interaction, potentiating p53-dependent cell cycle arrest
[60]. Ets domains are promising PPI inhibition targets, as
structural analysis illustrates multiple yet specific interaction
surfaces and potentially druggable pockets, e.g. a small
hydrophobic pocket in ELK4 accommodating the SRF
Leu155 side chain [11,12], and a cleft in GABPα binding
the GABPβ ankyrin repeat loops [47]. Although some Ets
interfaces are small, disruption may be adequate to abrogate
conformational movements that otherwise occur on binding
e.g. ETS1–PAX5 [11,12].
A significant development has been the isolation of YK-
4-279, an inhibitor of the oncogenic EWS–FLI1 Ets fusion
in Ewing’s sarcoma identified by library screening to inhibit
binding to its interactionpartnerRHA(RNAhelicaseA) [61].
Although YK-4-279 binds EWS–FLI1 weakly (Kd ∼10 µM),
it inhibits EWS–FLI1 in a dose-dependent manner in vivo
and in xenografts [61], with (S)-YK-4-279 determined as the
active enantiomer [62]. As EWS–FLI1 includes the FLI1 Ets
portion and some upstream regions, both RHA and YK-4-
279 potentially directly bind the Ets domain, particularly as
YK-4-279 also inhibits ERG and ETV1-mediated invasion
in prostate cancer [63]. YK-4-279, however, is likely to
inhibit PPIs other than RHA with ERG–ETV1, suggesting
a potentially different binding site for YK-4-279 [63].
Structural studies of the interaction of YK-4-279 would
augment current research, not only to identify the binding
site on EWS–FLI1 and ERG–ETV1, but also to assist in
structure-based drug design, increasing the affinity of YK-
4-279 for its targets to potentially increase its potency and
specificity for the Ets TF with which it interacts.
Concluding remarks
The structural biology of Ets DNAbinding is advanced, with
nuances of DNA-binding selectivity and autoinhibition well
studied [2]. The variety of Ets domain structures demonstrate
that, although Ets core architectures are similar and comprise
highly conserved sequences, they are versatile and encompass
multiple dynamic PPI surfaces, involving a variety of bonding
types. Although a number of heterodimeric Ets structures
have illustrated the role of interfaces in modulating DNA
binding, most Ets complex structures in the last decade
have been of homodimers. Although this has increased
understanding of the mechanism of autoinhibitory control,
a large number of structurally unresolved Ets interactions
remain. Structural analyses of such protein partnerships are
essential to elucidate the role of further interfaces such
as the Ets β-sheet face, particularly as many of these
partnerships play key roles in cancer.Hence further structural
studies are essential to assist drug targeting of Ets TFs in
cancer, to increase the scope of Ets surfaces available for
inhibition and to increase the potency of existing drugs.
Although Ets targeting has taken a huge step forward with
the development of the small-molecule inhibitor YK-4-279,
future structural analysis can assist drug development, from
resolvingmechanisms of inhibitor binding, to increasing drug
specificity and potency. Thus, as interactions, interfaces and
inhibition are closely linked, for any vote on the importance
of structural biology in Ets research, the ‘I’s certainly have it.
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